171 related articles for article (PubMed ID: 27452341)
21. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
22. Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC.
Escobar PA; Olivero OA; Wade NA; Abrams EJ; Nesel CJ; Ness RB; Day RD; Day BW; Meng Q; O'Neill JP; Walker DM; Poirier MC; Walker VE; Bigbee WL
Environ Mol Mutagen; 2007; 48(3-4):330-43. PubMed ID: 17358027
[TBL] [Abstract][Full Text] [Related]
23. Prenatal AZT or 3TC and mouse development of locomotor activity and hot-plate responding upon administration of the GABA(A) receptor agonist muscimol.
Ricceri L; Venerosi A; Valanzano A; Sorace A; Alleva E
Psychopharmacology (Berl); 2001 Feb; 153(4):434-42. PubMed ID: 11243490
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
[TBL] [Abstract][Full Text] [Related]
25. Zidovudine induces S-phase arrest and cell cycle gene expression changes in human cells.
Olivero OA; Tejera AM; Fernandez JJ; Taylor BJ; Das S; Divi RL; Poirier MC
Mutagenesis; 2005 Mar; 20(2):139-46. PubMed ID: 15784690
[TBL] [Abstract][Full Text] [Related]
26. Toxicity and genotoxicity induced by abacavir antiretroviral medication alone or in combination with zidovudine and/or lamivudine in Drosophila melanogaster.
Chen-Chen L; de Jesus Silva Carvalho C; de Moraes Filho AV; Véras JH; Cardoso CG; Bailão E; Spanó MA; Cunha KS
Hum Exp Toxicol; 2019 Apr; 38(4):446-454. PubMed ID: 30545272
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
McIntyre JA; Hopley M; Moodley D; Eklund M; Gray GE; Hall DB; Robinson P; Mayers D; Martinson NA
PLoS Med; 2009 Oct; 6(10):e1000172. PubMed ID: 19859531
[TBL] [Abstract][Full Text] [Related]
28. A pilot study to assess the immunologic and virologic efficacy of generic nevirapine, zidovudine and lamivudine in the treatment of HIV-1 infected women with pre-exposure to single dose nevirapine or short course zidovudine and their spouses in Chitungwiza, Zimbabwe.
Zijenah LS; Kadzirange G; Rusakaniko S; Kufa T; Gonah N; Tobaiwa O; Gwanzura C; Matsikire E; Katzenstein DA
Cent Afr J Med; 2006; 52(1-2):1-8. PubMed ID: 17892232
[TBL] [Abstract][Full Text] [Related]
29. Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice.
Venerosi A; Valanzano A; Alleva E; Calamandrei G
Teratology; 2001 Jan; 63(1):26-37. PubMed ID: 11169552
[TBL] [Abstract][Full Text] [Related]
30. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).
Gibb DM; Walker AS; Kaye S; De Rossi A; Ait-Khaled M; Pillay D; Muñoz-Fernandez MA; Loveday C; Compagnucci A; Dunn DT; Babiker AG
Antivir Ther; 2002 Dec; 7(4):293-303. PubMed ID: 12553485
[TBL] [Abstract][Full Text] [Related]
31. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
[TBL] [Abstract][Full Text] [Related]
32. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
33. Perinatal genotoxicity and carcinogenicity of anti-retroviral nucleoside analog drugs.
Poirier MC; Olivero OA; Walker DM; Walker VE
Toxicol Appl Pharmacol; 2004 Sep; 199(2):151-61. PubMed ID: 15313587
[TBL] [Abstract][Full Text] [Related]
34. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
Tetteh RA; Nartey ET; Lartey M; Mantel-Teeuwisse AK; Leufkens HG; Nortey PA; Dodoo AN
BMC Public Health; 2015 Jun; 15():573. PubMed ID: 26092496
[TBL] [Abstract][Full Text] [Related]
35. Assessment of complex genomic alterations induced by AZT, 3TC, and the combination AZT +3TC.
Grando AC; Guimarães NN; de Souza AP; Lehmann M; Cunha KS; Dihl RR
Drug Chem Toxicol; 2020 Jul; 43(4):429-434. PubMed ID: 30208744
[TBL] [Abstract][Full Text] [Related]
36. Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Feeney ER; van Vonderen MG; Wit F; Danner SA; van Agtmael MA; Villarroya F; Domingo P; Capeau J; Reiss P; Mallon PW;
AIDS; 2012 Nov; 26(17):2165-74. PubMed ID: 22874517
[TBL] [Abstract][Full Text] [Related]
37. Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC.
Dobrovolsky VN; Shaddock JG; Mittelstaedt RA; Bishop ME; Lewis SM; Lee FW; Aidoo A; Leakey JE; Dunnick JK; Heflich RH
Environ Mol Mutagen; 2007; 48(3-4):270-82. PubMed ID: 17358030
[TBL] [Abstract][Full Text] [Related]
38. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine.
Von Tungeln LS; Williams LD; Doerge DR; Shaddock JG; McGarrity LJ; Morris SM; Mittelstaedt RA; Heflich RH; Beland FA
Environ Mol Mutagen; 2007; 48(3-4):258-69. PubMed ID: 16850453
[TBL] [Abstract][Full Text] [Related]
39. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys.
Olivero OA; Anderson LM; Diwan BA; Haines DC; Harbaugh SW; Moskal TJ; Jones AB; Rice JM; Riggs CW; Logsdon D; Yuspa SH; Poirier MC
J Natl Cancer Inst; 1997 Nov; 89(21):1602-8. PubMed ID: 9362158
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
